These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. Ratain MJ; Eckhardt SG J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011 [No Abstract] [Full Text] [Related]
23. Resistance to epidermal growth factor receptor-targeted therapy. Morgillo F; Lee HY Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017 [TBL] [Abstract][Full Text] [Related]
24. [Chemotherapy of neoplasms in oncological departments]. Zelechowska JA Pol Tyg Lek; 1969 Dec; 24(50):1942-3. PubMed ID: 4904422 [No Abstract] [Full Text] [Related]
26. [Main problems of the method of clinical study of new antineoplastic agents]. Astrakhan VI Vestn Akad Med Nauk SSSR; 1966; 21(4):85-92. PubMed ID: 4882836 [No Abstract] [Full Text] [Related]
27. Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention? Lotan R Clin Cancer Res; 2000 Jun; 6(6):2126-8. PubMed ID: 10873060 [No Abstract] [Full Text] [Related]
29. Treatment for rare brain tumors veers from traditional tack. McBride G J Natl Cancer Inst; 1997 Jul; 89(13):912-3. PubMed ID: 9214668 [No Abstract] [Full Text] [Related]
30. [New drugs in early clinical trials and drug resistance--US-Japan joint seminar]. Ogawa M Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):697-700. PubMed ID: 2321989 [No Abstract] [Full Text] [Related]
31. The lingo of chemo. How language misleads patients with cancer. Napoli M Am J Nurs; 2000 Apr; 100(4):13. PubMed ID: 10776339 [No Abstract] [Full Text] [Related]
32. [The introduction of new drugs from the basic research to clinical application--issues in the drug development]. Watanabe T; Saijo N Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():289-91. PubMed ID: 7986105 [No Abstract] [Full Text] [Related]
33. [Targeted therapy: old and new possibilities]. Hochhaus A; Lüftner D; Mackensen A Onkologie; 2013; 36 Suppl 5():2-11. PubMed ID: 23921800 [No Abstract] [Full Text] [Related]
34. [Individualisation and "orphanization" in oncology]. Schenk M Dtsch Med Wochenschr; 2011 Apr; 136 Suppl 1():S27-30. PubMed ID: 21452104 [No Abstract] [Full Text] [Related]
35. [On the possibilities of using radioactive drugs]. Mitchell JS Strahlentherapie; 1965 Aug; 127(4):497-509. PubMed ID: 5321175 [No Abstract] [Full Text] [Related]
36. Compilation of 1982 Clinical Trials Summaries published in Cancer Treatment Reports. Cancer Treat Rep; 1982 Dec; 66(12):2101-3. PubMed ID: 6754078 [No Abstract] [Full Text] [Related]
37. Cancer drugs: restrictions recommended. Swinbanks D Nature; 1989 Dec 21-28; 342(6252):843. PubMed ID: 2687697 [No Abstract] [Full Text] [Related]